VTR Chart

1 Month

	Date	Diff	Articles
	2025-05-01	-6.48 %	Ventas (VTR) stock was down 6.48% following the announcement of a lawsuit against Viatris Inc. and its executives for alleged securities fraud related to misleading statements about the company's operational status and the adverse effects of a failed FDA inspection at its facility in India, which is expected to significantly impact revenue and earnings.
Ventas (VTR) stock was down 6.48% following the announcement of a lawsuit against Viatris Inc. and its executives for alleged securities fraud related to misleading statements about the company's operational status and the adverse effects of a failed FDA inspection at its facility in India, which is expected to significantly impact revenue and earnings. Ventas, Inc. (NYSE: VTR) stock experienced a drop of 6.48% after reaching a new 52-week high previously, likely due to profit-taking by investors following a strong earnings report, along with insider selling that may have raised concerns among shareholders. Ventas (VTR) stock experienced a decline of 6.48% due to the announcement of disappointing financial results and guidance from Viatris Inc., which was involved in a securities class action lawsuit for failing to disclose material information. Ventas (VTR) stock declined by 6.48% due to concerns regarding the impact of a recent FDA warning letter related to its Indore, India facility, which affected investor confidence and led to disappointing financial guidance.
	2025-04-30	+1.36 %	Ventas (VTR) stock increased by 1.36% likely as a reaction to the growing interest in a securities class action lawsuit against Viatris Inc., which prompted investors to reevaluate related investments.
Ventas (VTR) stock increased by 1.36% likely as a reaction to the growing interest in a securities class action lawsuit against Viatris Inc., which prompted investors to reevaluate related investments.
	2025-04-29	+0.93 %	Ventas (VTR) stock rose by 0.93% following news of a class action lawsuit against Viatris, Inc., indicating potential market reactions to legal developments rather than direct implications for VTR itself.
Ventas (VTR) stock rose by 0.93% following news of a class action lawsuit against Viatris, Inc., indicating potential market reactions to legal developments rather than direct implications for VTR itself. The article discusses a class action securities lawsuit against Viatris Inc. related to alleged securities fraud, which has impacted the company's stock performance, leading to a recent decline before a slight recovery. The reason for the recent increase in Viatris (VTRS) stock, which was up 0.93%, may stem from potential optimism from investors regarding the lawsuit and its implications, or a broader market trend affecting stock prices positively. Ventas (VTR) stock rose by 0.93% last night following a broader context of legal scrutiny regarding Viatris, Inc., which may have led to increased investor interest or confidence in VTR as a separate entity from the troubled Viatris, despite the latter's declining stock performance due to disappointing financial guidance related to operational issues and regulatory challenges. Ventas (VTR) stock rose by 0.93% due to positive market sentiment and analysts' ratings, with increased investments from major institutional investors indicating confidence in the stock's future performance.
	2025-04-28	+0.5 %	The article discusses a notice from The Gross Law Firm regarding class action proceedings for shareholders of Viatris Inc. (VTRS), following a significant drop in stock price due to misleading statements about the impact of a warning letter from the FDA on the company's operations, while the stock for Ventas, Inc. (VTR) rose by 0.5% for reasons not explicitly mentioned in the article. The increase in Ventas (VTR) stock could be attributed to market trends, positive investor sentiment, or broader economic factors that were not detailed in the article.
The article discusses a notice from The Gross Law Firm regarding class action proceedings for shareholders of Viatris Inc. (VTRS), following a significant drop in stock price due to misleading statements about the impact of a warning letter from the FDA on the company's operations, while the stock for Ventas, Inc. (VTR) rose by 0.5% for reasons not explicitly mentioned in the article. The increase in Ventas (VTR) stock could be attributed to market trends, positive investor sentiment, or broader economic factors that were not detailed in the article.
	2025-04-25	-0.37 %	Ventas (VTR) stock declined by 0.37% due to the fallout from a lawsuit against Viatris Inc. for potential securities law violations related to issues at its manufacturing facility, which led to significant financial repercussions and operational challenges for the company.
Ventas (VTR) stock declined by 0.37% due to the fallout from a lawsuit against Viatris Inc. for potential securities law violations related to issues at its manufacturing facility, which led to significant financial repercussions and operational challenges for the company. Ventas (VTR) stock fell by 0.37% due to broader market reactions linked to Viatris's recent class action lawsuit and disappointing financial performance, which includes missed earnings estimates and lowered guidance, affecting investor sentiment. Ventas (VTR) stock fell by 0.37% last night, likely due to its less favorable comparative performance against HA Sustainable Infrastructure Capital in key investment metrics such as revenue, potential for growth, and analysts' recommendations.
	2025-04-24	-0.34 %	The article discusses a class action securities lawsuit against Viatris Inc. (NASDAQ: VTRS) related to alleged securities fraud that has negatively impacted the company's stock, which fell substantially due to misrepresentations regarding a warning letter from the FDA concerning its Indore, India facility. The decline in stock price is primarily attributed to Viatris' poor financial guidance linked to the impact of this warning letter and import alert.
The article discusses a class action securities lawsuit against Viatris Inc. (NASDAQ: VTRS) related to alleged securities fraud that has negatively impacted the company's stock, which fell substantially due to misrepresentations regarding a warning letter from the FDA concerning its Indore, India facility. The decline in stock price is primarily attributed to Viatris' poor financial guidance linked to the impact of this warning letter and import alert. Ventas (VTR) stock declined by 0.34% due to disappointing fiscal guidance and material disclosures related to a securities class action lawsuit against Viatris Inc. for not revealing significant information during the class period, which negatively impacted investor confidence.
	2025-04-23	+0.51 %	Ventas (VTR) stock rose by 0.51% amidst ongoing legal issues faced by Viatris Inc., which has been sued for potential securities law violations related to a failed FDA inspection that negatively impacted its financial outlook.
Ventas (VTR) stock rose by 0.51% amidst ongoing legal issues faced by Viatris Inc., which has been sued for potential securities law violations related to a failed FDA inspection that negatively impacted its financial outlook. Viatris Inc. (NASDAQ:VTRS) stock increased by 0.51% as it is recognized as one of the best cheap stocks to buy under $10, showing strong growth potential through its diverse healthcare offerings and significant new product revenues, coupled with positive market sentiment amid recent discussions about potential easing of economic uncertainties. The increase in Viatris (VTRS) stock can be attributed to its strong financial performance indications, ongoing product development, and the broader positive market trends discussed by analysts. The article discusses an investigation into Viatris, Inc. (VTRS) by Faruqi & Faruqi LLP regarding potential securities law violations and lawsuits following a significant drop in the company's stock price due to disappointing financial guidance after an FDA warning letter. Ventas (VTR) stock's recent 0.51% increase could potentially be attributed to investor sentiment stabilizing after previous declines linked to the announcement of the class action lawsuit against Viatris rather than specific positive news regarding Ventas itself. Ventas (VTR) stock recently increased by 0.51%, likely due to positive sentiment surrounding its performance compared to other inexpensive stocks and the overall market outlook. The article discusses a notice issued by The Gross Law Firm to shareholders of Viatris Inc. (NASDAQ: VTRS), who may be eligible to participate in a class-action lawsuit due to allegedly misleading statements made by the company's management regarding regulatory issues, which contributed to a significant stock price drop following disappointing financial results. Ventas (VTR) stock was not mentioned in relation to a reason for its increase; however, if it went up, it could be attributed to broader market trends or investor reactions to different news, as the article focuses primarily on Viatris (VTRS) and its legal situation.
	2025-04-21	-1.65 %	The article reports on a class action securities lawsuit against Viatris Inc. (NASDAQ: VTRS) related to allegations of securities fraud, which has contributed to a significant decline in its stock price; specifically, the stock fell approximately 15.21% following disappointing financial results linked to regulatory issues with the company's Indore, India facility, leading to a -1.65% drop in VTR's stock. The decline in the stock is primarily attributed to concerns surrounding a warning letter from the FDA regarding Viatris' Indore facility, which was downplayed by the company and ultimately impacted its financial guidance negatively, resulting in a sharp drop in stock value.
The article reports on a class action securities lawsuit against Viatris Inc. (NASDAQ: VTRS) related to allegations of securities fraud, which has contributed to a significant decline in its stock price; specifically, the stock fell approximately 15.21% following disappointing financial results linked to regulatory issues with the company's Indore, India facility, leading to a -1.65% drop in VTR's stock. The decline in the stock is primarily attributed to concerns surrounding a warning letter from the FDA regarding Viatris' Indore facility, which was downplayed by the company and ultimately impacted its financial guidance negatively, resulting in a sharp drop in stock value. Ventas, Inc. (NYSE: VTR) stock decreased by 1.65% after Guggenheim Capital LLC significantly reduced its holdings in the company by 76.1%, alongside other institutional investor activity that may have contributed to market sentiment affecting the stock. Ventas (VTR) stock fell by 1.65% in response to a lawsuit filed against Viatris Inc. for potential federal securities law violations related to the company's misleading statements about its operations following a failed FDA inspection that significantly impacted its revenue and earnings projections. Ventas (VTR) stock decreased by 1.65% amid concerns surrounding a class action lawsuit against Viatris, Inc. related to securities fraud and disappointing financial results, including lower-than-expected guidance and issues with a manufacturing facility. The article reports that Viatris, Inc. (NASDAQ: VTRS) experienced a decline of 1.65% in its stock price due to the announcement of a class action lawsuit alleging securities fraud and the company's poor financial performance and lowered guidance for 2025.
	2025-04-17	+0.44 %	The article discusses a class action lawsuit filed against Viatris, Inc. (NASDAQ: VTRS) alleging securities fraud, following disappointing financial results and lower guidance for 2025, which previously caused the stock price to drop significantly. Ventas (VTR) stock may have risen by 0.44% due to broader market trends or specific investor sentiment, rather than being directly related to the issues faced by Viatris.
The article discusses a class action lawsuit filed against Viatris, Inc. (NASDAQ: VTRS) alleging securities fraud, following disappointing financial results and lower guidance for 2025, which previously caused the stock price to drop significantly. Ventas (VTR) stock may have risen by 0.44% due to broader market trends or specific investor sentiment, rather than being directly related to the issues faced by Viatris. Ventas (VTR) stock rose by 0.44% last night as it continues to attract interest from institutional investors and analysts, particularly following positive earnings results and a dividend increase. Ventas (VTR) stock rose by 0.44% due to investor optimism following a lawsuit announcement against Viatris Inc. for securities law violations, which may indicate a perception of potential legal repercussions impacting Viatris negatively in the market and indirectly benefiting related stocks. Ventas (VTR) stock rose by 0.44% following the announcement of a securities class action lawsuit against Viatris, which may have prompted investor interest and optimism amidst the ongoing situation. Ventas (VTR) stock was up 0.44% due to increased investor interest in response to the upcoming June 3, 2025 deadline for filing claims related to a class action lawsuit against Viatris Inc., which has implications for investor confidence and market activity.
	2025-04-16	-0.22 %	Ventas (VTR) stock decreased by 0.22% due to the filing of a securities class action lawsuit against Viatris Inc. for failing to disclose material information, combined with disappointing financial guidance announced by the company, which negatively affected investor sentiment.
Ventas (VTR) stock decreased by 0.22% due to the filing of a securities class action lawsuit against Viatris Inc. for failing to disclose material information, combined with disappointing financial guidance announced by the company, which negatively affected investor sentiment. Ventas (VTR) stock experienced a decline of 0.22%, likely influenced by broader market trends and negative developments related to Viatris, which includes missed earnings expectations and decreased guidance for future performance. Ventas (VTR) stock was down 0.22% following the announcement of a class action lawsuit against Viatris Inc. (VTRS) for allegedly misleading investors about the negative impacts of a failed FDA inspection at its facility in India, which has affected its financial performance.